International Conference on Brain Disorders and Therapeutics
Fraunhofer Institute for Cell Therapy and Immunology, Germany
Hans-Ulrich Demuth has completed his PhD at the age of 28 and his doctorate of sciences at the age of 36 years from Martin-Luther-University, Halle/S., Germany. He did postdoctoral studies at University of Kansas and the Uppsala Biomedical Research Center. He has inaugurated and co-founded Probiodrug in 1997, the company which has developed the concept of inhibition of Dipeptidylpeptidase-4 as treatment of type-2 diabetes (on the market since 2006). He has published more than 300 papers in reputed journals and has been serving as an editorial board member and reviewer of repute. In 2013 he founded the Fraunhofer-IZI department MWT.
Abstract : Targeting Neurotoxic N-Terminal Pyroglutamated Abeta (Pgluaβ) with inhibitors of Glutaminyl Cyclase (Qc) and Pgluaβ-specific antibodies has reached clinical stage
Notice: Undefined index: tittle in /var/www/universal_code/speaker-details.php on line 312